Cerebral Rhizomucor Infection Treated by Posaconazole Delayed-Release Tablets in an Allogeneic Stem Cell Transplant Recipient

Détails

ID Serval
serval:BIB_C9735292E9B9
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Titre
Cerebral Rhizomucor Infection Treated by Posaconazole Delayed-Release Tablets in an Allogeneic Stem Cell Transplant Recipient
Périodique
Int J Infect Dis
Auteur⸱e⸱s
Andrey D. O., Kaiser L., Emonet S., Erard V., Chalandon Y., van Delden C.
ISSN
1878-3511 (Electronic)
ISSN-L
1201-9712
Statut éditorial
Publié
Date de publication
02/2017
Volume
55
Pages
24-26
Langue
anglais
Notes
Andrey, Diego O
Kaiser, Laurent
Emonet, Stephane
Erard, Veronique
Chalandon, Yves
van Delden, Christian
eng
Case Reports
Canada
Int J Infect Dis. 2017 Feb;55:24-26. doi: 10.1016/j.ijid.2016.12.014. Epub 2016 Dec 14.
Résumé
Mucormycosis (zygomycosis) is an emerging fungal disease in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. A 30-year-old woman diagnosed with acute myelomonocytic leukemia and needing allo-HSCT presented pulmonary and cerebral infection due to Rhizomucor pusillus. This fungal infection was treated with surgical treatment and posaconazole delayed-release tablets. This strategy allowed reaching high drug levels that could not be obtained with the posaconazole solution.
Mots-clé
Adult, Antifungal Agents/*therapeutic use, Delayed-Action Preparations, Fatal Outcome, Female, Humans, Immunocompromised Host, Leukemia, Myelomonocytic, Acute/immunology/*surgery, Mucormycosis/diagnosis/*drug therapy/immunology/*microbiology, Rhizomucor/drug effects, *Stem Cell Transplantation, Tablets, Transplantation, Homologous, Triazoles/*therapeutic use, Mucormycosis, Posaconazole delayed-release tablets, Rhizomucor pusillus, Zygomycosis
Pubmed
Création de la notice
25/02/2022 16:43
Dernière modification de la notice
26/02/2022 7:35
Données d'usage